Basit öğe kaydını göster

dc.contributor.authorBilgici A.
dc.contributor.authorKuru Ö.
dc.contributor.authorAkdeniz O.
dc.date.accessioned2020-06-21T09:24:04Z
dc.date.available2020-06-21T09:24:04Z
dc.date.issued2004
dc.identifier.issn1300-0691
dc.identifier.urihttps://hdl.handle.net/20.500.12712/3731
dc.description.abstractMany rheumatic disease affect women of childbearing age, and all the medications used to treat these diseases may affect conception, pregnancy, fetal development, and lactation. However, most drugs are not tested in pregnant women, are not labeled for use during pregnancy. Absence of sufficient available information is a more important problem for both the physician and the patients. Physicians who care for these women need to be aware of the potential adverse effects of these medications, and which medications can be used safely prior to conception and during pregnancy and lactation. Also men who take cytotoxic drugs should be informed of the risks of impaired fertility and teratogenicity.en_US
dc.language.isoturen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectArthritisen_US
dc.subjectFertilityen_US
dc.subjectLactationen_US
dc.subjectPregnancyen_US
dc.subjectTherapyen_US
dc.titleThe use of immunosuppressive and anti-inflammatory medications in the younger patients with inflammatory arthritisen_US
dc.title.alternativeİnflamatuvar artri?tli? genç hastalarda i?mmünsüpresi?f ve anti?i?nflamatuvar i?laçlarin kullanimien_US
dc.typereviewen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume15en_US
dc.identifier.issue1en_US
dc.identifier.startpage50en_US
dc.identifier.endpage60en_US
dc.relation.journalJournal of Rheumatology and Medical Rehabilitationen_US
dc.relation.publicationcategoryDiğeren_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster